DiaMedica Therapeutics (DMAC) Common Equity (2017 - 2026)

DiaMedica Therapeutics' Common Equity history runs 10 years deep, the most recent figure standing at $47.2 million for Q1 2026.

• On a quarterly basis, Common Equity rose 39.11% year-over-year to $47.2 million in Q1 2026; TTM through Mar 2026 was $47.2 million, a 39.11% increase from a year earlier, with the FY2025 full-year figure at $56.1 million, up 37.8% from the prior year.
• Common Equity retreated to $47.2 million in Q1 2026 per DMAC's latest filing, from $56.1 million in the prior quarter.
• Across five years, Common Equity topped out at $59.7 million in Q2 2023 and bottomed at $27.0 million in Q1 2023.
• The 5-year median for Common Equity is $46.3 million (2024), against an average of $43.7 million.
• Across the five-year window, Common Equity soared 85.62% in 2022 and tumbled 49.13% in 2025, its largest moves.
• Year by year, Common Equity stood at $31.8 million in 2022, then surged by 60.42% to $51.1 million in 2023, then retreated by 20.25% to $40.7 million in 2024, then jumped by 37.8% to $56.1 million in 2025, then retreated by 15.82% to $47.2 million in 2026.
• Per Business Quant, the three latest DMAC Common Equity figures stand at $47.2 million (Q1 2026), $56.1 million (Q4 2025), and $51.6 million (Q3 2025).